NYSE:NSC Norfolk Southern Q1 2025 Earnings Report $217.69 +3.66 (+1.71%) As of 10:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Norfolk Southern EPS ResultsActual EPSN/AConsensus EPS $2.87Beat/MissN/AOne Year Ago EPSN/ANorfolk Southern Revenue ResultsActual RevenueN/AExpected Revenue$3.01 billionBeat/MissN/AYoY Revenue GrowthN/ANorfolk Southern Announcement DetailsQuarterQ1 2025Date4/23/2025TimeBefore Market OpensConference Call DateWednesday, April 23, 2025Conference Call Time8:45AM ETConference Call ResourcesEarnings HistoryCompany Profile Remove Ads Amylyx Pharmaceuticals Earnings HeadlinesKuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law FirmApril 16 at 3:56 PM | gurufocus.comKuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law FirmApril 16 at 2:00 PM | globenewswire.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 17, 2025 | Porter & Company (Ad)Is Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) the Best Biotech Penny Stock to Buy According to Hedge Funds?April 16 at 12:04 PM | msn.comAmylyx doses first participant in LUMINA trialApril 9, 2025 | markets.businessinsider.comAmylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral SclerosisApril 9, 2025 | businesswire.comSee More Amylyx Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Amylyx Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Amylyx Pharmaceuticals and other key companies, straight to your email. Email Address About Amylyx PharmaceuticalsAmylyx Pharmaceuticals (NASDAQ:AMLX), a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.View Amylyx Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Reasons to Like the Look of Amazon Ahead of EarningsTesla Stock Eyes Breakout With Earnings on DeckJohnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth Ahead Upcoming Earnings HDFC Bank (4/18/2025)Tesla (4/22/2025)Intuitive Surgical (4/22/2025)Verizon Communications (4/22/2025)Canadian National Railway (4/22/2025)Novartis (4/22/2025)RTX (4/22/2025)3M (4/22/2025)Capital One Financial (4/22/2025)General Electric (4/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
